Development Services and cGMP Manufacturing of Highly Productive Mammalian Cell Lines

Collaboration Offers a Powerful Combination of cGMP Manufacturing and Ubiquitous Chromatin Opening Elements (UCOE®) Expression Technology

LIVERPOOL, United Kingdom & RESEARCH TRIANGLE PARK, N.C.–Eden Biodesign Ltd. and Millipore Corporation today announced a partnership that will provide biopharmaceutical companies with access to a powerful combination of Eden’s cGMP manufacturing and Millipore’s Ubiquitous Chromatin Opening Elements (UCOE®) expression technology.

“We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”

As part of this agreement, Eden Biodesign will employ Millipore’s proprietary UCOE® expression technology to undertake mammalian cell line development projects and cGMP production for third-party clients.

Millipore’s UCOE® technology provides major improvements in gene expression for stably transfected mammalian cells through effects on the structure of chromatin. Cells developed using Millipore’s UCOE® technology are stable high-expressors, which means it is much easier and faster for biopharmaceutical manufacturers to identify high-yielding clones with the productivity and stability required for biomanufacturing than with many other expression systems.

“We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Roger Lias, Ph.D., president of Eden Biodesign’s North American subsidiary. “Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”

“Millipore is committed to bringing innovation that solves critical biopharmaceutical manufacturing business needs. Our distinctive UCOE® technology, with its high expression elements, revolutionizes the speed by which protein therapeutics can be produced in mammalian cells,” said Andrew Bulpin, Ph.D., Vice President, Upstream Processing for Millipore’s Bioprocess Division. “We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”

About Eden Biodesign

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design, process development and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for commercializing biopharmaceutical products and processes, the company offers expertise and guidance in multiple sectors. Eden Biodesign’s world class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensure that Eden Biodesign offers much more than a traditional CMO. Find out more at www.EdenBiodesign.com.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.